Livsayis (cemdisiran) is approved by the FDA as the first and only siRNA treatment in generalized myasthenia gravis and a single treatment in a subcutaneous dose four times a year -. Company announcement - FT.com.
Livsayis (cemdisiran) is approved by the FDA as the first and only siRNA treatment in generalized myasthenia gravis and a single treatment in a subcutaneous dose four times a year -. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in